… in patients with coronavirus disease 2019 (COVID-19). … damage in patients with COVID-19.
Numerous randomized clinical … the point about using biopharmaceutical drugs in COVID-19. …

… caused by coronavirus disease 2019 (COVID-19), efficient and specific therapies are
urgently needed. Compared with traditional small-molecular drugs, antibody therapies are …

… antibodies (nAbs) in the clinical management of COVID-19 … by the US Food and Drug
Administration for the treatment of … monotherapy for use in COVID-19 patients who do not require …

… To help address the emergent information needs, our “Tracker” provides a useful reference
for researchers and the public to track current progress of drugs developed for COVID-19. …

… antibodies. This has led to combinations of different monoclonal antibodies or the development
of monoclonal antibodies … antibodies is mostly confined to mildly affected COVID-19 …

… efforts to design effecting drugs to treat COVID-19 infection, but no vaccine or curative drug
has been found … As monoclonal antibodies could neutralize other coronaviruses biotherapy of …

… anti-malaria drug hydroxychloroquine found to be a treatment option for COVID-19. A non-…
plus azithromycin treatment reduced the viral load in COVID-19 patients [8]. Following this …

… COVID-19 or who require oxygen therapy due to COVID-19 or any other underlying non-COVID-19 …
findings demonstrated limited benefits of the drug in patients suffering from severe …

… of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic
drugs, … research, antibody development and traditional Chinese medicine. Among all these …

… Transcriptomics, proteomics, and interactomics studies have further revealed many other
potential drug targets for COVID-19 therapeutics development 13 - 19 . Hundreds of …